PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
34.37%
Some net income increase while AGEN is negative at -202.30%. John Neff would see a short-term edge over the struggling competitor.
0.63%
Some D&A expansion while AGEN is negative at -1.19%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
-79.79%
Negative yoy SBC while AGEN is 104.96%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-121.40%
Both reduce yoy usage, with AGEN at -127.48%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-200.00%
Negative yoy AP while AGEN is 100.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-91.42%
Both reduce yoy usage, with AGEN at -100.15%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
2.52%
Some yoy increase while AGEN is negative at -170.14%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-18.12%
Both yoy CFO lines are negative, with AGEN at -129.69%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
100.00%
CapEx growth of 100.00% while AGEN is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We expand invests by 100.00% while AGEN is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative yoy issuance while AGEN is 61.89%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.